Arrayjet business expansion translates into job creation and fuels next generation bio-printing technology
- Posted: 05/05/17
The hiring drive strikes at Arrayjet, as we continue to increase staff levels and grow our international sales development pipeline. Many of world’s leading universities, pharmaceuticals and biomedical research institutes are looking to increase accuracy, speed and throughput of their drug discovery and life science applications by using Arrayjet’s inkjet range of bio-printing instrumentation and services. This growing demand has fuelled work on new generation of bio-printing technology and a new product launch aimed in 2018.
Seven new jobs have been created across Arrayjet’s core science, engineering and commercial units with the new recruits expanding the staff levels to 25. Arrayjet has also expanded into new markets since 2016 and has increased its presence in existing key markets. Arrayjet now has a presence in 27 countries.
Recently joining our team are David Crabb as Chief Engineer; Maya Kowalewska, Application Scientist; Catriona Ford, Senior Applications Scientist; Ranald Pringle, Commercial Manager, Europe & Middle East; Gavin Boothroyd, Commercial Manager, North America; Andrew Tomlins, Commercial Manager, Asia Pacific; and a new start to assist with administrative activities.
Additionally, existing staff have been given responsibility for new territories. Saloni Sonawala has split her role as Business Development Executive to assume responsibility of developing new business opportunities across the Indian subcontinent, whilst Russell Brown now has overall responsibility for Arrayjet’s Commercial Operations. There are three additional engineering roles being created later in 2017.
Iain McWilliam, Chief Executive Officer, Arrayjet comments; "A recent heavily oversubscribed round of funding via Archangel Investment Syndicate and a strong year on year 25% revenue growth is testament to our proven ability to develop and nurture new business. An appetite for new business and a belief in our business model underpinned 2016 as a year in which we continued a programme of successful expansion. Arrayjet is on a very sound footing as a profitable, expanding, Scottish-based and international player in the biomedical sector.”
Archangel Investors co-founder, Mike Rutterford, said: “Arrayjet remains one of the shining beacons within the Scottish life sciences industry and the new appointments, healthy international order book and, most importantly, the vision to establish and grow new territories underlines just how vital this business is to the life sciences landscape in Scotland.”
Read more at: The Scotman